PhotoCure ASA v Queen's University at Kingston

Link copied
Case Copied 81 min read

FEDERAL COURT OF AUSTRALIA

PhotoCure ASA v Queen’s University at Kingston [2005] FCA 344

PATENTS – invention claimed for a method of detection and treatment of malignant and non-malignant lesions by photochemotherapy – whether patent invalid on grounds of obviousness, lack of novelty, lack of sufficiency and best method, lack of definition or lack of fair basis – whether the patent is infringed in substance by a variant that does not have a material effect on the way the invention works – consideration of the principles to be applied in determining a claim of infringement in substance when no claim is infringed on a textual approach to construction of the patent

Patents Act 1990 (Cth) ss 7, 40(2)(a), 40(2)(b), 117, 138(3)(b) and 234 and Sch 1
Patents Act 1952 (Cth) s 100(1)(e)

Amadio Pty Ltd v Henderson (1998) 81 FCR 149
Minnesota Mining & Manufacturing Co v Tyco Electronics Pty Ltd (2002) 56 IPR 248
NV Philips Gloeilampenfabrieken v Mirabella International Pty Ltd (1993) 44 FCR 239
Aktiebolaget Hässle v Alphapharm Pty Limited (2002) 212 CLR 411
General Tire & Rubber Company v The Firestone Tyre and Rubber Company Ltd [1972] RPC 457
The Leonardis v Sartas No 1 Pty Ltd (1996) 67 FCR 126
ICI Chemicals & Polymers Ltd v Lubrizol Corporation Inc (1999) 45 IPR 577
Minnesota Mining and Manufacturing Co v Beiersdorf (Australia) Ltd (1980) 144 CLR 253
Aktiebolaget Hässle v Alphapharm Pty Ltd (2000) 51 IPR 375
Aktiebolaget Hässle v Alphapharm Pty Ltd (1999) 44 IPR 593
Williams Advanced Materials, Inc v Target Technology Company LLC [2004] FCA 1405
Nescor Industries Group Pty Ltd v Miba Pty Ltd (1997) 150 ALR 633
Chiron Corporation v Organon Teknika Ltd (No 3) [1994] FSR 202
ICI Chemicals & Polymers Ltd v The Lubrizol Corporation Inc (2000) 106 FCR 214
Meyers Taylor Pty Ltd v Vicarr Industries Ltd (1977) 137 CLR 228
R D Werner & Co Inc v Bailey Aluminium Products Pty Ltd (1989) 25 FCR 565
Bristol-Myers Squibb Company v FH Faulding & Co Ltd (2000) 97 FCR 524
Nicaro Holdings Pty Ltd v Martin Engineering Co (1990) 91 ALR 513
Hills v Evans (1862) 31 LJ Ch 457
Olin Corporation v Super Cartridge Co. Pty Ltd (1977) 180 CLR 236
Arrow Pharmaceuticals Ltd v Merck & Co Inc (2004) 213 ALR 182
Rescare Ltd v Anaesthetic Supplies Pty Ltd (1992) 111 ALR 205
Kimberly-Clark Australia Pty Limited v Arico Trading International Pty Limited (2001) 207 CLR 1
Innovative Agriculture Products Pty Ltd v Cranshaw (1996) 35 IPR 643
Electric & Musical Industries Ltd v Lissen Ltd [1938] 4 All ER 221
Welch Perrin and Company Pty Ltd v Worrel (1961) 106 CLR 588
Kauzal v Lee (1936) 58 CLR 670
Raleigh Cycle Co Ltd v H Miller & Co Ltd [1948] 1 All ER 308
General Steel Industries Inc v State of New South Wales (1967) 40 ALJR 464
Windsurfing International Inc v Petit [1984] 2 NSWLR 196
Philpott v Hanbury (1885) 2 RPC 33
Rose…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read PhotoCure ASA v Queen's University at Kingston and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2005] FCA 344
Decision Date

CaseChat Overview and Summary

PhotoCure ASA, the patent proprietor, brought an application to revoke a patent held by Queen's University at Kingston, which involved the use of photodetection and photodynamic therapy (PDT) for the detection and treatment of cancers and lesions. DUSA Pharmaceutical Inc. filed a cross-claim alleging that PhotoCure had infringed its patent rights. The key issues before the court were whether the patent was valid and whether DUSA had infringed PhotoCure's patent rights. The court examined the claims of the patent, the relevant prior art, and the meanings of specific terms within the claims. It also considered whether the claimed invention was obvious in light of the prior art.

The court found that the patent was valid and that DUSA had not infringed PhotoCure's patent rights. The court held that the terms "administering to the patient" and "5-aminolevulinic acid" had their primary meanings within the claims, and that compliance with these terms was an essential requirement of the invention. The court also found that the claimed invention was not obvious in light of the prior art. The court noted that the prior art disclosed the use of porphyrins for PDT, but did not disclose the use of 5-aminolevulinic acid, which was a key component of the claimed invention. The court further found that the claimed invention was not obvious to a person skilled in the art, as it required a specific combination of elements that were not suggested or taught by the prior art.

In conclusion, the court dismissed PhotoCure's application to revoke the patent and DUSA's cross-claim for infringement. The court held that each party was to bear its own costs of and incidental to the application and cross-claim. The court found that the patent was valid and that DUSA had not infringed PhotoCure's patent rights. The court also held that the claimed invention was not obvious in light of the prior art, and that the terms within the claims had their primary meanings.

Orders

Orders of the court

1. The application and the cross-claim be dismissed.

2. Each of the parties is to bear its own costs of and incidental to the application and cross-claim.

Background

Background to the litigation

There were very few points or issues that were not contested. In order to prevent these reasons from being unacceptably long I have confined them to the significant and consequential issues that were both relied on in submissions and are capable of affecting the outcome of the dispute: see Amadio Pty Ltd v Henderson (1998) 81 FCR 149 at 175.2. Background facts The invention involves the use of photodetection and photodynamic therapy (“PDT”) for the detection and treatment of certain cancers and lesions or abnormalities (“lesions”). Photodetection and PDT are medical procedures involving the delivery to, or production in, the lesions of a photosensitive chemical compound. Photodetection involves exposing lesions to a certain wavelength of light thereby causing them to fluoresce and hence enable their detection. PDT involves exposing lesions to a wavelength of light that causes the photosensitised cells to be destroyed. One of the inventors, Professor Kennedy, describes the process as follows:“PDT involves the interaction of photons of light of suitable (photoactivating) wavelengths with molecules of photosensitiser. When the energy of a photon of light is absorbed by a molecule of photosensitiser, that energy may be transferred by direct contact to a molecule of oxygen, thus producing an energized molecule of oxygen that is chemically quite reactive, called singlet oxygen. Singlet oxygen is capable of reacting with and destroying a wide variety of vital cellular structures. If the damage is severe enough, cell death follows. All else being equal, the higher the concentration of intracellular photosensitizer, the greater will be the production of activated oxygen in the presence of photoactivating light and the higher the probability that exposure of photosensitized tissues to light will lead to phototoxic cell death. However, very low concentrations of photosensitizer will have little or no effect on cell viability, since any minor cell damage that might be produced can quickly be repaired.” At the priority date, the photosensitising agents most commonly used in photodetection and PDT were substances called porphyrins. Porphyrins are naturally occurring chemical compounds in the human body which have fluorescent and photosensitive qualities. For PDT to function effectively a sufficient amount of porphyrins needs to accumulate in the targeted lesions with only minimal amounts accumulating in the surrounding normal tissue. The preferential accumulation of porphyrins in lesions is significant because it allows the precise area of the lesions to be identified when exposed to a light. The light then causes fluorescence of the porphyrins and allows those lesions to be destroyed while leaving the surrounding normal tissue undamaged. This accumulation of a photosensitising agent preferentially in abnormal tissue (as compared to the surrounding healthy tissue) is referred to in the art as “selectivity” or “specificity”. When PDT and photodetection function effectively they can have significant advantages over other more established methods of cancer detection and treatment. Photodetection allows diagnosis before the cancer has grown to a size that would make its malignancy apparent in the normal course of events. It can also enable the identification of small secondary cancers, the presence of which might otherwise be overlooked. The ability of PDT to destroy malignant cells leaving healthy tissue unharmed gives it an advantage over traditional cancer treatments such as chemotherapy or radiotherapy, both of which can occasion significant damage to healthy tissue. The invasiveness and imprecision in the case of surgery are additional problems that are absent in PDT when it is effective.

Evidence

Evidence Before The Court

Decision

Reasons for decision

MERKEL J
It may not be strictly necessary to address the third Improver question as the answer to the second question has the consequence that, applying a purposive approach to the construction of the claims, there is no proper basis for concluding that the primary meanings of “administering to the patient” and “5-aminolevulinic acid” in the claims were not the intended meanings. However, it is also clear that the answer to the third Improver question is that the reader skilled in the art would have understood that compliance with the primary meaning of those phrases was an essential requirement of the invention. I would add that it was not, and could not be, disputed that “administering to the patient” and “5-aminolevulinic acid” were essential integers. Thus, DUSA has not made out its case on infringement.6. Conclusion In the result, PhotoCure’s application for revocation of the patent is to be dismissed and DUSA’s cross-claim for infringement must also be dismissed. Because so many of the issues raised on the application and the cross-claim were closely related, it would be an almost impossible task to separate the substantial costs incurred in relation to the application from the substantive costs incurred in relation to the cross-claim. For example, a great deal of the extensive evidence relating to obviousness was relevant to both the application and the cross-claim. In the circumstances, which include DUSA’s success on the application and PhotoCure’s success on the cross-claim, I am of the view that the fair and reasonable outcome is for each of the parties to bear its own costs of and incidental to the application and the cross-claim.

Ratio Decidendi

Legal Principle Established

Established by: MERKEL J